
|Articles|May 20, 2020
Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC
The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.
Advertisement
The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Dr. Angela Smith, of UNC Lineberger Comprehensive Cancer Center, regarding the significance of this approval for providers and patients. The interview took place on May 1, 2020. Dr. Smith serves on the study advisory committee for UroGen Pharma.
Advertisement
Related to this article

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
Advertisement
Advertisement
Trending on Urology Times
1
AUA kidney stone guideline: Assessing risk for recurrent stone formation
2
FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC
3
Rethinking Testosterone Therapy After the FDA Label Revisions
4
Pearls & Perspectives: Exploring Radiofrequency Therapy for Erectile Dysfunction, With Mohit Khera, MD
5
